German Larrain, MD
Interventional Cardiology · Wausau, WINPI 1508845090
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Abbott at 24.1% of the total. 2025 is the largest year on record at $8,767, 2.1 times the $4,191 reported in 2019.
Across 299 payments — averaging $127.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Boston Scientific$5K
- Edwards Lifesciences$5K
- Penumbra, Inc.$5K
- Medtronic$5K
- Heartflow, Inc.$3K
- plus $7K from 22 others
Across 196 payments — averaging $3986.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Operations, Inc.$159K
- Abbott$141K
- Amgen$138K
- Medtronic$109K
- AstraZeneca$92K
- CSL Behring$61K
- plus $81K from 4 others
What the payments were for
- Consulting fees$2,7027%
- Travel & lodging$16,43243%
- Food & beverage$18,86949%
- Education$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 84 | $9,176 |
| Boston Scientific | 30 | $5,149 |
| Edwards Lifesciences | 43 | $4,768 |
| Penumbra, Inc. | 12 | $4,680 |
| Medtronic(2 entities) | 37 | $4,511 |
| Heartflow, Inc. | 13 | $2,540 |
| Inari Medical, Inc. | 16 | $1,883 |
| GE HealthCare | 3 | $916 |
| Abiomed | 11 | $733 |
| Atricure, Inc. | 4 | $464 |
| AstraZeneca | 4 | $443 |
| Novartis | 4 | $322 |
| Pfizer | 3 | $291 |
| Shockwave Medical, Inc | 3 | $290 |
| Amgen | 5 | $262 |
| Siemens Medical Solutions USA, Inc. | 4 | $251 |
| Artivion, Inc. | 2 | $217 |
| Novo Nordisk | 5 | $210 |
| Angiodynamics, Inc. | 2 | $207 |
| Regeneron Healthcare Solutions, Inc. | 1 | $126 |
| Bayer | 2 | $125 |
| Philips North America LLC | 1 | $118 |
| Daxor Corporation | 1 | $110 |
| Livanova USA, Inc. | 3 | $101 |
| Stryker | 3 | $93 |
| Johnson & Johnson | 1 | $77 |
| Merck | 1 | $66 |
| Getinge USA Sales, LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$4,680
- AMPLATZER AMULET$3,799
- GENERAL VASCULAR ACCESS$3,436
- CoreValve Evolut$2,784
- FFRct$2,286
- FLOWTRIEVER CATHETER, S$1,523
- CT THROMBECTOMY SYSTEM KIT$1,523
- Epic$1,469
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,377
- NAVITOR$670
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$556
- GENERAL - THERAPIES$480
- Trifecta GT Tissue Heart Valve$394
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$389
- SYMPLICITY G3$355
- Mitra Clip system$276
- Epic Stented Tissue Valve$274
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$265
- ENTRESTO$250
- WATCHMAN FLX$244
How this compares
$38,154 in reported general payments places this provider in the 85th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 612 | $671,816 |
| EntrestoSacubitril/Valsartan | 201 | $249,355 |
| VyndamaxTafamidis | 11 | $248,210 |
| XareltoRivaroxaban | 157 | $175,379 |
| JardianceEmpagliflozin | 169 | $173,259 |
| Repatha SureclickEvolocumab | 152 | $134,022 |
| MultaqDronedarone Hcl | 54 | $83,654 |
| Praluent PenAlirocumab | 30 | $35,886 |
| OzempicSemaglutide | 16 | $23,873 |
| FarxigaDapagliflozin Propanediol | 14 | $17,618 |
| CorlanorIvabradine Hcl | 14 | $12,206 |
| Metoprolol Succinate | 832 | $11,142 |
| Atorvastatin Calcium | 937 | $8,437 |
| Ezetimibe | 362 | $7,158 |
| Bumetanide | 229 | $6,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $291 | $920,027623 claims |
| NovartisEntresto | $322 | $249,355201 claims |
| Johnson & JohnsonXarelto | $77 | $175,379157 claims |
| Novo NordiskOzempic | $210 | $23,87316 claims |
| AstraZenecaFarxiga | $443 | $17,61814 claims |
| AmgenCorlanor | $262 | $12,20614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Wausau
- Mark HoffmannWausau$52K
- Marcus SubletteWausau$38K
- Pavel GuigauriWausau$4K
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Raaid MuseitifKenosha$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.